Alcohol and risk of liver cancer

Share This Post

Does alcohol increases the risk of liver cancer ? For this question, we got affirmative answers from some experts and professors at the Medical Academic Medical Center of the University of Southern California. Excessive drinking can cause liver cancer, which is a fact that has been established. If diagnosed early, patients have more treatment options, so screening is the key.

So, what are the causes of liver cancer? In most cases, liver cancer is caused by cirrhosis, which is caused by inflammation and scarring of liver cells. There are three main causes of cirrhosis: hepatitis B and hepatitis C viruses; non-alcoholic steatohepatitis (NASH). NASH is caused by fatty liver, and its risk factors include obesity, gastric bypass surgery, high cholesterol and type 2 diabetes. Some NASH patients directly develop liver cancer without cirrhosis. Overweight and alcoholics also face double risks. The third reason is alcoholic liver disease.

Most occasional social drinkers will not contract alcoholic cirrhosis. A reliable way to protect yourself from alcoholic liver disease is to avoid drinking altogether. People who drink a lot of alcohol have a greater risk of liver cancer. Therefore, people who drink too much should be screened for liver cancer. The screening process is simple and non-invasive, and the doctor will perform an ultrasound examination of the liver to detect cysts, obstructions or infections in the liver and to check for cancer. If an abnormality is found on the ultrasound, the doctor will determine if you need additional tests, such as CT scans, MRI, or alpha-fetal protein tests, which can identify the tumor.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy